Testing ammoxetine for depression
Treatments studied
Part of Mental health clinical trials.
This trial tests an investigational medication called ammoxetine for people with moderate to severe depression. It aims to see if the drug can reduce depressive symptoms and is for those who haven't had success with certain other antidepressants.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with major depressive disorder, either for the first time (for at least 3 months) or as a relapse (for at least 1 month).
- Your depression is currently moderate to severe based on standard rating scales.
- You have not had suicidal thoughts or attempts recently.
- You are not taking certain other medications or have certain medical conditions that would interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how a medication called memantine affects memory and mood in people with major depression who are not currently taking antidepressants. It involves MRI scans and may help find new ways to treat depression.
This study tests a new combination of two medications (dextromethorphan and bupropion) as a treatment for major depressive disorder. It may be an option if you have not already tried many antidepressants that didn't work.
This trial tests an investigational medication for adults with major depressive disorder who are currently taking an antidepressant but still have symptoms. It aims to see if adding this new drug can improve mood better than a placebo.
This study tests an investigational drug called KH607 for adults with major depressive disorder (MDD). It aims to see if the drug can safely and effectively reduce depression symptoms.
This Phase 2 trial tests whether an NMDA-targeted treatment can improve symptoms of major depressive disorder (MDD). You may be able to join if your depression diagnosis and symptom score fit, and you meet several safety and study-following requirements.
This trial tests a new oral medication, GM-2505, for people with moderate to severe major depressive disorder (MDD). The goal is to see if it is safe and well-tolerated, either as a stand-alone treatment or alongside a stable SSRI/SNRI antidepressant.
Hear when a new Major Depressive Disorder (MDD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.